FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:459-465 August 12, 1993 Number 7 Next

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

ABSTRACT

Background Many patients with non-Hodgkin's lymphomas are not cured by current therapies, and new approaches to treatment are needed. As part of an ongoing phase 1 study, we examined the effect of radioimmunotherapy with ¹³¹I-labeled B-cell-specific anti-CD20 monoclonal antibody in 10 patients with CD20-positive B-cell lymphomas in whom primary chemotherapy had failed.

Methods and Results Anti-B1 (anti-CD20) mouse monoclonal antibody trace-labeled with ¹³¹I (15 mg containing 5 mCi) was given intravenously at approximately one-week intervals: first, without pretreatment with unlabeled anti-B1 antibody, to all 10 patients; then with pretreatment with 135 mg of unlabeled antibody, to 8 patients; and then, with pretreatment with 685 mg, to 2 patients. Serial quantitative gamma-camera images and measures of whole-body radioactivity were obtained after each tracer dose. All known disease sites larger than 2 cm could be imaged. The effect of a pretreatment dose of unlabeled anti-B1 antibody on targeting of the tumor with the radiolabeled antibody was variable.

The pretreatment dose of unlabeled antibody that produced the highest ratio of the tumor dose to the whole-body dose in tracer studies was then used to deliver higher doses of radioactivity for radioimmunotherapy in nine patients. Three patients received doses designed to deliver 25 cGy to the whole body (two patients treated twice, six to eight weeks apart), four patients received 35 cGy (one patient treated twice), and two patients received 45 cGy (one patient treated twice); each dose contained 34 to 66 mCi of activity. Six of the nine treated patients had tumor responses, including patients with bulky or chemotherapy-resistant disease: four patients had complete remissions, and two had partial responses. Three patients had objective responses to tracer infusions before they received radioimmunotherapeutic doses. Of the four patients with complete remissions, one remained in remission for eight months and the other three continue to have no disease progression (for 11, 9, and 8 months). There was mild or no myelosuppression.

Conclusions Radioimmunotherapy with [¹³¹I]anti-B1 antibody is a promising new treatment for lymphoma.

Source Information

From the Divisions of Hematology/Oncology (M.S.K., A.W.M., J.M.B.) and Nuclear Medicine (K.R.Z., S.D.M., S.M.C., N.A.P., R.L.W.), Department of Internal Medicine, and the Departments of Radiology (I.R.F., R.L.W.) and Pathology (C.W.R.), University of Michigan, Ann Arbor; and the Coulter Corporation (G.M.B., S.D.G.), Hialeah, Fla.

Address reprint requests to Dr. Kaminski at the Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan Medical Center, 102 Observatory St., Ann Arbor, MI 48109-0724.

Full Text of this Article

This article has been cited by other articles:

• Press, O. W. (2008). Evidence Mounts for the Efficacy of Radioimmunotherapy for B-Cell Lymphomas. JCO 26: 5147-5150 [Full Text]  
• Gopal, A. K., Press, O. W., Wilbur, S. M., Maloney, D. G., Pagel, J. M. (2008). Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab. Blood 112: 830-835 [Abstract] [Full Text]  
• Meyer zum Buschenfelde, C., Feuerstacke, Y., Gotze, K. S., Scholze, K., Peschel, C. (2008). GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment. Cancer Res. 68: 5414-5422 [Abstract] [Full Text]  
• Buchegger, F., Press, O. W., Delaloye, A. B., Ketterer, N. (2008). Radiolabeled and Native Antibodies and the Prospect of Cure of Follicular Lymphoma. The Oncologist 13: 657-667 [Abstract] [Full Text]  
• Kapadia, N. S., Engles, J. M., Wahl, R. L. (2008). In Vitro Evaluation of Radioprotective and Radiosensitizing Effects of Rituximab. JNM 49: 674-678 [Abstract] [Full Text]  
• Bodet-Milin, C., Kraeber-Bodere, F., Dupas, B., Morschhauser, F., Gastinne, T., Le Gouill, S., Campion, L., Harousseau, J.-L., Wegener, W. A., Goldenberg, D. M., Huglo, D. (2008). Evaluation of response to fractionated radioimmunotherapy with 90Y-epratuzumab in non-Hodgkin's lymphoma by 18F-fluorodeoxyglucose positron emission tomography. haematol 93: 390-397 [Abstract] [Full Text]  
• Jacene, H. A., Filice, R., Kasecamp, W., Wahl, R. L. (2007). Comparison of 90Y-Ibritumomab Tiuxetan and 131I-Tositumomab in Clinical Practice. JNM 48: 1767-1776 [Abstract] [Full Text]  
• Leahy, M. F., Seymour, J. F., Hicks, R. J., Turner, J. H. (2006). Multicenter Phase II Clinical Study of Iodine-131-Rituximab Radioimmunotherapy in Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma. JCO 24: 4418-4425 [Abstract] [Full Text]  
• Sharkey, R. M., Goldenberg, D. M. (2006). Targeted Therapy of Cancer: New Prospects for Antibodies and Immunoconjugates. CA Cancer J Clin 56: 226-243 [Abstract] [Full Text]  
• Hamaguchi, Y., Xiu, Y., Komura, K., Nimmerjahn, F., Tedder, T. F. (2006). Antibody isotype-specific engagement of Fc{gamma} receptors regulates B lymphocyte depletion during CD20 immunotherapy. JEM 203: 743-753 [Abstract] [Full Text]  
• Pagel, J. M., Appelbaum, F. R., Eary, J. F., Rajendran, J., Fisher, D. R., Gooley, T., Ruffner, K., Nemecek, E., Sickle, E., Durack, L., Carreras, J., Horowitz, M. M., Press, O. W., Gopal, A. K., Martin, P. J., Bernstein, I. D., Matthews, D. C. (2006). 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. Blood 107: 2184-2191 [Abstract] [Full Text]  
• Fisher, R. I., Kaminski, M. S., Wahl, R. L., Knox, S. J., Zelenetz, A. D., Vose, J. M., Leonard, J. P., Kroll, S., Goldsmith, S. J., Coleman, M. (2005). Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin's Lymphomas. JCO 23: 7565-7573 [Abstract] [Full Text]  
• Scott, A. M., Lee, F.-T., Jones, R., Hopkins, W., MacGregor, D., Cebon, J. S., Hannah, A., Chong, G., U, P., Papenfuss, A., Rigopoulos, A., Sturrock, S., Murphy, R., Wirth, V., Murone, C., Smyth, F. E., Knight, S., Welt, S., Ritter, G., Richards, E., Nice, E. C., Burgess, A. W., Old, L. J. (2005). A Phase I Trial of Humanized Monoclonal Antibody A33 in Patients with Colorectal Carcinoma: Biodistribution, Pharmacokinetics, and Quantitative Tumor Uptake. Clin. Cancer Res. 11: 4810-4817 [Abstract] [Full Text]  
• Bennett, J. M., Kaminski, M. S., Leonard, J. P., Vose, J. M., Zelenetz, A. D., Knox, S. J., Horning, S., Press, O. W., Radford, J. A., Kroll, S. M., Capizzi, R. L. (2005). Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood 105: 4576-4582 [Abstract] [Full Text]  
• Shen, S., DeNardo, S. J., Richman, C. M., Yuan, A., Siantar, C. H., O'Donnell, R. T., Kroger, L. A., DeNardo, G. L. (2005). Planning Time for Peripheral Blood Stem Cell Infusion After High-Dose Targeted Radionuclide Therapy Using Dosimetry. JNM 46: 1034-1041 [Abstract] [Full Text]  
• Shen, S., Forero, A., LoBuglio, A. F., Breitz, H., Khazaeli, M.B., Fisher, D. R., Wang, W., Meredith, R. F. (2005). Patient-Specific Dosimetry of Pretargeted Radioimmunotherapy Using CC49 Fusion Protein in Patients with Gastrointestinal Malignancies. JNM 46: 642-651 [Abstract] [Full Text]  
• Hamaguchi, Y., Uchida, J., Cain, D. W., Venturi, G. M., Poe, J. C., Haas, K. M., Tedder, T. F. (2005). The Peritoneal Cavity Provides a Protective Niche for B1 and Conventional B Lymphocytes during Anti-CD20 Immunotherapy in Mice. J. Immunol. 174: 4389-4399 [Abstract] [Full Text]  
• Kaminski, M. S., Tuck, M., Estes, J., Kolstad, A., Ross, C. W., Zasadny, K., Regan, D., Kison, P., Fisher, S., Kroll, S., Wahl, R. L. (2005). 131I-Tositumomab Therapy as Initial Treatment for Follicular Lymphoma. NEJM 352: 441-449 [Abstract] [Full Text]  
• Horning, S. J., Younes, A., Jain, V., Kroll, S., Lucas, J., Podoloff, D., Goris, M. (2005). Efficacy and Safety of Tositumomab and Iodine-131 Tositumomab (Bexxar) in B-Cell Lymphoma, Progressive After Rituximab. JCO 23: 712-719 [Abstract] [Full Text]  
• Palomba, M. L., Roberts, W. K., Dao, T., Manukian, G., Guevara-Patino, J. A., Wolchok, J. D., Scheinberg, D. A., Houghton, A. N. (2005). CD8+ T-Cell-Dependent Immunity Following Xenogeneic DNA Immunization against CD20 in a Tumor Challenge Model of B-Cell Lymphoma. Clin. Cancer Res. 11: 370-379 [Abstract] [Full Text]  
• Larson, S. M., Krenning, E. P. (2005). A Pragmatic Perspective on Molecular Targeted Radionuclide Therapy. JNM 46: 1S-3S [Full Text]  
• Sharkey, R. M., Goldenberg, D. M. (2005). Perspectives on Cancer Therapy with Radiolabeled Monoclonal Antibodies. JNM 46: 115S-127S [Abstract] [Full Text]  
• Wahl, R. L. (2005). Tositumomab and 131I Therapy in Non-Hodgkin's Lymphoma. JNM 46: 128S-140S [Abstract] [Full Text]  
• Davis, T. A., Kaminski, M. S., Leonard, J. P., Hsu, F. J., Wilkinson, M., Zelenetz, A., Wahl, R. L., Kroll, S., Coleman, M., Goris, M., Levy, R., Knox, S. J. (2004). The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy. Clin. Cancer Res. 10: 7792-7798 [Abstract] [Full Text]  
• Schaffland, A. O., Buchegger, F., Kosinski, M., Antonescu, C., Paschoud, C., Grannavel, C., Pellikka, R., Delaloye, A. B. (2004). 131I-Rituximab: Relationship Between Immunoreactivity and Specific Activity. JNM 45: 1784-1790 [Abstract] [Full Text]  
• Adams, G. P., Shaller, C. C., Dadachova, E., Simmons, H. H., Horak, E. M., Tesfaye, A., Klein-Szanto, A. J. P., Marks, J. D., Brechbiel, M. W., Weiner, L. M. (2004). A Single Treatment of Yttrium-90-labeled CHX-A''-C6.5 Diabody Inhibits the Growth of Established Human Tumor Xenografts in Immunodeficient Mice. Cancer Res. 64: 6200-6206 [Abstract] [Full Text]  
• Uchida, J., Hamaguchi, Y., Oliver, J. A., Ravetch, J. V., Poe, J. C., Haas, K. M., Tedder, T. F. (2004). The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor-dependent Mechanisms during Anti-CD20 Antibody Immunotherapy. JEM 199: 1659-1669 [Abstract] [Full Text]  
• Du, Y., Honeychurch, J., Cragg, M. S., Bayne, M., Glennie, M. J., Johnson, P. W. M., Illidge, T. M. (2004). Antibody-induced intracellular signaling works in combination with radiation to eradicate lymphoma in radioimmunotherapy. Blood 103: 1485-1494 [Abstract] [Full Text]  
• Uchida, J., Lee, Y., Hasegawa, M., Liang, Y., Bradney, A., Oliver, J. A., Bowen, K., Steeber, D. A., Haas, K. M., Poe, J. C., Tedder, T. F. (2004). Mouse CD20 expression and function. Int Immunol 16: 119-129 [Abstract] [Full Text]  
• Sharkey, R. M., Brenner, A., Burton, J., Hajjar, G., Toder, S. P., Alavi, A., Matthies, A., Tsai, D. E., Schuster, S. J., Stadtmauer, E. A., Czuczman, M. S., Lamonica, D., Kraeber-Bodere, F., Mahe, B., Chatal, J.-F., Rogatko, A., Mardirrosian, G., Goldenberg, D. M. (2003). Radioimmunotherapy of Non-Hodgkin's Lymphoma with 90Y-DOTA Humanized Anti-CD22 IgG (90Y-Epratuzumab): Do Tumor Targeting and Dosimetry Predict Therapeutic Response?. JNM 44: 2000-2018 [Abstract] [Full Text]  
• Wong, J. Y. C., Shibata, S., Williams, L. E., Kwok, C. S., Liu, A., Chu, D. Z., Yamauchi, D. M., Wilczynski, S., Ikle, D. N., Wu, A. M., Yazaki, P. J., Shively, J. E., Doroshow, J. H., Raubitschek, A. A. (2003). A Phase I Trial of 90Y-Anti-Carcinoembryonic Antigen Chimeric T84.66 Radioimmunotherapy with 5-Fluorouracil in Patients with Metastatic Colorectal Cancer. Clin. Cancer Res. 9: 5842-5852 [Abstract] [Full Text]  
• Gopal, A. K., Gooley, T. A., Maloney, D. G., Petersdorf, S. H., Eary, J. F., Rajendran, J. G., Bush, S. A., Durack, L. D., Golden, J., Martin, P. J., Matthews, D. C., Appelbaum, F. R., Bernstein, I. D., Press, O. W. (2003). High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. Blood 102: 2351-2357 [Abstract] [Full Text]  
• DeNardo, G. L., Mirick, G. R., Kroger, L. A., Bradt, B. M., Lamborn, K. R., DeNardo, S. J. (2003). Characterization of Human IgG Antimouse Antibody in Patients with B-Cell Malignancies. Clin. Cancer Res. 9: 4013S-4021 [Abstract] [Full Text]  
• Tuscano, J. M., O'Donnell, R. T., Miers, L. A., Kroger, L. A., Kukis, D. L., Lamborn, K. R., Tedder, T. F., DeNardo, G. L. (2003). Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts. Blood 101: 3641-3647 [Abstract] [Full Text]  
• Zhang, M., Zhang, Z., Garmestani, K., Schultz, J., Axworthy, D. B., Goldman, C. K., Brechbiel, M. W., Carrasquillo, J. A., Waldmann, T. A. (2003). Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts. Proc. Natl. Acad. Sci. USA 100: 1891-1895 [Abstract] [Full Text]  
• Sgouros, G., Squeri, S., Ballangrud, A. M., Kolbert, K. S., Teitcher, J. B., Panageas, K. S., Finn, R. D., Divgi, C. R., Larson, S. M., Zelenetz, A. D. (2003). Patient-Specific, 3-Dimensional Dosimetry in Non-Hodgkin's Lymphoma Patients Treated with 131I-anti-B1 Antibody: Assessment of Tumor Dose-Response. JNM 44: 260-268 [Abstract] [Full Text]  
• Cheson, B. D. (2003). Radioimmunotherapy of non-Hodgkin lymphomas. Blood 101: 391-398 [Abstract] [Full Text]  
• Zanzonico, P. B. (2002). Model-Based Versus Patient-Specific Dosimetry: Blurring the Lines. JNM 43: 1665-1666 [Full Text]  
• Alain, T., Hirasawa, K., Pon, K. J., Nishikawa, S. G., Urbanski, S. J., Auer, Y., Luider, J., Martin, A., Johnston, R. N., Janowska-Wieczorek, A., Lee, P. W. K., Kossakowska, A. E. (2002). Reovirus therapy of lymphoid malignancies. Blood 100: 4146-4153 [Abstract] [Full Text]  
• Juweid, M. E. (2002). Radioimmunotherapy of B-Cell Non-Hodgkin's Lymphoma: From Clinical Trials to Clinical Practice. JNM 43: 1507-1529 [Abstract] [Full Text]  
• Witzig, T. E., Gordon, L. I., Cabanillas, F., Czuczman, M. S., Emmanouilides, C., Joyce, R., Pohlman, B. L., Bartlett, N. L., Wiseman, G. A., Padre, N., Grillo-Lopez, A. J., Multani, P., White, C. A. (2002). Randomized Controlled Trial of Yttrium-90-Labeled Ibritumomab Tiuxetan Radioimmunotherapy Versus Rituximab Immunotherapy for Patients With Relapsed or Refractory Low-Grade, Follicular, or Transformed B-Cell Non-Hodgkin's Lymphoma. JCO 20: 2453-2463 [Abstract] [Full Text]  
• Kaminski, M. S., Zelenetz, A. D., Press, O. W., Saleh, M., Leonard, J., Fehrenbacher, L., Lister, T. A., Stagg, R. J., Tidmarsh, G. F., Kroll, S., Wahl, R. L., Knox, S. J., Vose, J. M. (2001). Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin's Lymphomas. JCO 19: 3918-3928 [Abstract] [Full Text]  
• Clarke, S E M (2001). Advances in radionuclide imaging: radionuclide imaging as a guide to therapy. Imaging 13: 171-184 [Abstract] [Full Text]  
• Schnipper, L. E., Strom, T. B. (2001). A Magic Bullet for Cancer -- How Near and How Far?. NEJM 345: 283-284 [Full Text]  
• Rutar, F. J., Augustine, S. C., Colcher, D., Siegel, J. A., Jacobson, D. A., Tempero, M. A., Dukat, V. J., Hohenstein, M. A., Gobar, L. S., Vose, J. M. (2001). Outpatient Treatment with 131I-Anti-B1 Antibody: Radiation Exposure to Family Members. JNM 42: 907-915 [Abstract] [Full Text]  
• McCall, A. M., Shahied, L., Amoroso, A. R., Horak, E. M., Simmons, H. H., Nielson, U., Adams, G. P., Schier, R., Marks, J. D., Weiner, L. M. (2001). Increasing the Affinity for Tumor Antigen Enhances Bispecific Antibody Cytotoxicity. J. Immunol. 166: 6112-6117 [Abstract] [Full Text]  
• Ballangrud, A. M., Yang, W.-H., Charlton, D. E., McDevitt, M. R., Hamacher, K. A., Panageas, K. S., Ma, D., Bander, N. H., Scheinberg, D. A., Sgouros, G. (2001). Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591). Cancer Res. 61: 2008-2014 [Abstract] [Full Text]  
• Goel, A., Augustine, S., Baranowska-Kortylewicz, J., Colcher, D., Booth, B. J. M., Pavlinkova, G., Tempero, M., Batra, S. K. (2001). Single-Dose versus Fractionated Radioimmunotherapy of Human Colon Carcinoma Xenografts Using 131I-labeled Multivalent CC49 Single-chain Fvs. Clin. Cancer Res. 7: 175-184 [Abstract] [Full Text]  
• Press, O. W., Leonard, J. P., Coiffier, B., Levy, R., Timmerman, J. (2001). Immunotherapy of Non-Hodgkin's Lymphomas. ASH Education Book 2001: 221-240 [Abstract] [Full Text]  
• Wong, J. Y. C., Chu, D. Z., Yamauchi, D. M., Williams, L. E., Liu, A., Wilczynski, S., Wu, A. M., Shively, J. E., Doroshow, J. H., Raubitschek, A. A. (2000). A Phase I Radioimmunotherapy Trial Evaluating 90Yttrium-labeled Anti-Carcinoembryonic Antigen (CEA) Chimeric T84.66 in Patients with Metastatic CEA-producing Malignancies. Clin. Cancer Res. 6: 3855-3863 [Abstract] [Full Text]  
• Hainsworth, J. D. (2000). Monoclonal Antibody Therapy in Lymphoid Malignancies. The Oncologist 5: 376-384 [Abstract] [Full Text]  
• Kaminski, M. S., Estes, J., Zasadny, K. R., Francis, I. R., Ross, C. W., Tuck, M., Regan, D., Fisher, S., Gutierrez, J., Kroll, S., Stagg, R., Tidmarsh, G., Wahl, R. L. (2000). Radioimmunotherapy with iodine 131I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 96: 1259-1266 [Abstract] [Full Text]  
• Pai-Scherf, L. H., Carrasquillo, J. A., Paik, C., Gansow, O., Whatley, M., Pearson, D., Webber, K., Hamilton, M., Allegra, C., Brechbiel, M., Willingham, M. C., Pastan, I. (2000). Imaging and Phase I Study of 111In- and 90Y-labeled Anti-LewisY Monoclonal Antibody B3. Clin. Cancer Res. 6: 1720-1730 [Abstract] [Full Text]  
• Axworthy, D. B., Reno, J. M., Hylarides, M. D., Mallett, R. W., Theodore, L. J., Gustavson, L. M., Su, F.-M., Hobson, L. J., Beaumier, P. L., Fritzberg, A. R. (2000). Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA 97: 1802-1807 [Abstract] [Full Text]  
• Apostolidis, J., Gupta, R. K., Grenzelias, D., Johnson, P. W. M., Pappa, V. I., Summers, K. E., Salam, A., Adams, K., Norton, A. J., Amess, J. A. L., Matthews, J., Bradburn, M., Lister, T. A., Rohatiner, A. Z. S. (2000). High-Dose Therapy With Autologous Bone Marrow Support as Consolidation of Remission in Follicular Lymphoma: Long-Term Clinical and Molecular Follow-Up. JCO 18: 527-527 [Abstract] [Full Text]  
• Witzig, T. E., White, C. A., Wiseman, G. A., Gordon, L. I., Emmanouilides, C., Raubitschek, A., Janakiraman, N., Gutheil, J., Schilder, R. J., Spies, S., Silverman, D. H.S., Parker, E., Grillo-Lopez, A. J. (1999). Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20+ B-Cell Non-Hodgkin's Lymphoma. JCO 17: 3793-3803 [Abstract] [Full Text]  
• Freedman, A. S., Neuberg, D., Mauch, P., Soiffer, R. J., Anderson, K. C., Fisher, D. C., Schlossman, R., Alyea, E. P., Takvorian, T., Jallow, H., Kuhlman, C., Ritz, J., Nadler, L. M., Gribben, J. G. (1999). Long-Term Follow-Up of Autologous Bone Marrow Transplantation in Patients With Relapsed Follicular Lymphoma. Blood 94: 3325-3333 [Abstract] [Full Text]  
• Matthews, D. C., Appelbaum, F. R., Eary, J. F., Fisher, D. R., Durack, L. D., Hui, T. E., Martin, P. J., Mitchell, D., Press, O. W., Storb, R., Bernstein, I. D. (1999). Phase I Study of 131I-Anti-CD45 Antibody Plus Cyclophosphamide and Total Body Irradiation for Advanced Acute Leukemia and Myelodysplastic Syndrome. Blood 94: 1237-1247 [Abstract] [Full Text]  
• Illidge, T. M., Cragg, M. S., McBride, H. M., French, R. R., Glennie, M. J. (1999). The Importance of Antibody-Specificity in Determining Successful Radioimmunotherapy of B-Cell Lymphoma. Blood 94: 233-243 [Abstract] [Full Text]  
• Behr, T. M., Behe, M., Stabin, M. G., Wehrmann, E., Apostolidis, C., Molinet, R., Strutz, F., Fayyazi, A., Wieland, E., Gratz, S., Koch, L., Goldenberg, D. M., Becker, W. (1999). High-Linear Energy Transfer (LET) {{alpha}} versus Low-LET {beta} Emitters in Radioimmunotherapy of Solid Tumors: Therapeutic Efficacy and Dose-limiting Toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' Fragments in a Human Colonic Cancer Model. Cancer Res. 59: 2635-2643 [Abstract] [Full Text]  
• Ridgway, J. B. B., Ng, E., Kern, J. A., Lee, J., Brush, J., Goddard, A., Carter, P. (1999). Identification of a Human Anti-CD55 Single-Chain Fv by Subtractive Panning of a Phage Library Using Tumor and Nontumor Cell Lines. Cancer Res. 59: 2718-2723 [Abstract] [Full Text]  
• Kuan, C.-T., Reist, C. J., Foulon, C. F., Lorimer, I. A. J., Archer, G., Pegram, C. N., Pastan, I., Zalutsky, M. R., Bigner, D. D. (1999). 125I-labeled Anti-Epidermal Growth Factor Receptor-vIII Single-Chain Fv Exhibits Specific and High-Level Targeting of Glioma Xenografts. Clin. Cancer Res. 5: 1539-1549 [Abstract] [Full Text]  
• Shan, D., Press, O. W., Tsu, T. T., Hayden, M. S., Ledbetter, J. A. (1999). Characterization of scFv-Ig Constructs Generated from the Anti-CD20 mAb 1F5 Using Linker Peptides of Varying Lengths. J. Immunol. 162: 6589-6595 [Abstract] [Full Text]  
• Shan, D., Ledbetter, J. A., Press, O. W. (1998). Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies. Blood 91: 1644-1652 [Abstract] [Full Text]  
• Maloney, D. G., Grillo-Lopez, A. J., White, C. A., Bodkin, D., Schilder, R. J., Neidhart, J. A., Janakiraman, N., Foon, K. A., Liles, T.-M., Dallaire, B. K., Wey, K., Royston, I., Davis, T., Levy, R. (1997). IDEC-C2B8 (Rituximab) Anti-CD20 Monoclonal Antibody Therapy in Patients With Relapsed Low-Grade Non-Hodgkin's Lymphoma. Blood 90: 2188-2195 [Abstract] [Full Text]  
• Gidlof, C., Dohlsten, M., Lando, P., Kalland, T., Sundstrom, C., Totterman, T. H. (1997). A Superantigen-Antibody Fusion Protein for T-Cell Immunotherapy of Human B-Lineage Malignancies. Blood 89: 2089-2097 [Abstract] [Full Text]  
• Vose, J. M. (1995). Treatment for Non-Hodgkin's Lymphoma in Relapse -- What Are the Alternatives?. NEJM 333: 1565-1566 [Full Text]  
• Press, O. W., Eary, J. F., Appelbaum, F. R., Martin, P. J., Badger, C. C., Nelp, W. B., Glenn, S., Butchko, G., Fisher, D., Porter, B., Matthews, D. C., Fisher, L. D., Bernstein, I. D. (1993). Radiolabeled-Antibody Therapy of B-Cell Lymphoma with Autologous Bone Marrow Support. NEJM 329: 1219-1224 [Abstract] [Full Text]  
• Bast, R. C. (1993). Progress in Radioimmunotherapy. NEJM 329: 1266-1268 [Full Text]